Hepatitis C drug telaprevir reduced the virus to an undetectable level in 75% of clinical-trial patients who received the standard dose in combination with interferon and ribavirin, Vertex Pharmaceuticals reported. The study focused on patients with Genotype 1 hepatitis C who had not received treatment before the trial.

Related Summaries